The surge in cell, gene, and biologic therapies has pushed global biotechs to rely heavily on CDMOs for manufacturing excellence. CDMOs provide essential GMP facilities, skilled teams, and streamlined processes that support faster clinical entry and commercial readiness. With rising regulatory expectations and limited in-house resources, biotechs partner with CDMOs to de-risk developm... https://xellera.livejournal.com/4599.html